SCHEMBL9963142

SCHEMBL9963142

CC(C)N1CCCC(S(=O)(=O)c2ccc(Br)cc2)C1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 2/20 0.39
ATM Q13315 1/20 0.38
PIK3CA P42336 1/20 0.37
NAMPT P43490 2/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
MMP1 P03956 1/20 0.35
MMP8 P22894 1/20 0.35
MMP13 P45452 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12835945 0.81 ATM (0.40) ATMMAPK1HTTHCRTR1HCRTR2
SCHEMBL14983620 0.78 LMNA (0.51) PIK3CANAMPTHTTLMNAGAA
SCHEMBL14941033 0.78 ATM (0.38) ATMMAPK1HTTHCRTR1HCRTR2
SCHEMBL20003165 0.77 HTR2A (0.45) PIK3CANAMPTDRD2
SCHEMBL12049945 0.77 HTR2A (0.50) PIK3CANAMPTDRD2
SCHEMBL28022948 0.75 POLB (0.43) NAMPTGAA
SCHEMBL1939864 0.75 MAPK1 (0.53) NAMPTMAPK1HTTGAAMMP1
SCHEMBL25296150 0.73 MAPK1 (0.56) NAMPTMAPK1HTTGAAMMP1
SCHEMBL25797549 0.73 FPR3 (0.32) HTR6PIK3CANAMPTMMP1MMP13
SCHEMBL9963145 0.73 PIK3CA (0.36) HTR6PIK3CALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 HTR6 748/4885ATM 3949/4885PIK3CA 2748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.